0001192482-18-000002.txt : 20180102
0001192482-18-000002.hdr.sgml : 20180102
20180102160712
ACCESSION NUMBER: 0001192482-18-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171228
FILED AS OF DATE: 20180102
DATE AS OF CHANGE: 20180102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCP Vitalife Partners (Israel) II, L.P.
CENTRAL INDEX KEY: 0001602484
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36329
FILM NUMBER: 18501830
BUSINESS ADDRESS:
STREET 1: 32B HABARZEL STREET
STREET 2: RAMAT HACHAYAL
CITY: TEL AVIV
STATE: L3
ZIP: 69710
BUSINESS PHONE: 610-995-2900
MAIL ADDRESS:
STREET 1: SUITE 190
STREET 2: 7 GREAT VALLEY PARKWAY
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Recro Pharma, Inc.
CENTRAL INDEX KEY: 0001588972
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261523233
STATE OF INCORPORATION: PA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 LAPP ROAD
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (484) 395-2400
MAIL ADDRESS:
STREET 1: 490 LAPP ROAD
CITY: MALVERN
STATE: PA
ZIP: 19355
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-12-28
0001588972
Recro Pharma, Inc.
REPH
0001602484
SCP Vitalife Partners (Israel) II, L.P.
SUITE 190
7 GREAT VALLEY PARKWAY
MALVERN,
PA
19355
0
0
1
0
Common Stock
2017-12-28
4
S
0
1980
9.4395
D
744708
D
Common Stock
2017-12-29
4
S
0
4110
9.1948
D
740598
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.3600 to $9.5300, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.0650 to $9.4300, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
/s/ Ryan Lake, Attorney-in-fact
2018-01-02